Future Program: Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID)

SOL #: DARPA-SN-26-77Special Notice

Overview

Buyer

DEPT OF DEFENSE
Defense Advanced Research Projects Agency (Darpa)
DEF ADVANCED RESEARCH PROJECTS AGCY
ARLINGTON, VA, 222032114, United States

Place of Performance

Place of performance not available

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

National Defense R&D Services; Department Of Defense Military; Applied Research (AC12)

Set Aside

No set aside specified

Timeline

1
Posted
May 1, 2026
2
Action Date
May 19, 2026, 11:59 PM

Qualification Details

Fit reasons
  • NAICS alignment with historical contract wins in similar service areas.
  • Scope strongly matches core technical capabilities and delivery model.
Risks
  • Past performance thresholds may require one additional teaming partner.
  • Potential clarification needed on staffing minimums before bid/no-bid.
Next steps

Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.

Quick Summary

DARPA's Biological Technologies Office (BTO) has issued a Special Notice for its forthcoming Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program. This notice serves as a future program announcement, not a formal solicitation, to inform potential bidders about additional research areas of interest. The RAPIID program aims to develop a shelf-stable, scalable blood analog system within three years.

Program Overview

The RAPIID program seeks to deliver a comprehensive blood analog system, including components such as oxygen carriers, plasma, and platelet-like particles. This system will be paired with integrated delivery systems and diagnostic tools. The program is structured in two phases over a total of 36 months:

  • Phase 1 (12 months): Focus on component viability and compatibility.
  • Phase 2 (24 months): Covers preclinical and clinical development, regulatory strategy, manufacturing scale-up, and commercialization. DARPA encourages specialization, welcoming proposals for specific blood analog components or enabling technologies rather than requiring a full system from a single entity.

Contract & Timeline

  • Type: Special Notice (Future Program Announcement)
  • Published: May 1, 2026
  • Set-Aside: None specified
  • Product Service Code: AC12 - National Defense R&D Services; Department Of Defense Military; Applied Research

Action Items

Interested parties can sign up for future program updates by emailing RAPIID@darpa.mil. The full solicitation, when released, will be made available on SAM.gov. DARPAConnect is also available as a resource for understanding how to do business with the agency.

Contact Information

People

Points of Contact

LCDR Robert Murray, DARPA/BTOPRIMARY
RAPIID@darpa.mil

Files

Files

Download

Versions

Version 1Viewing
Special Notice
Posted: May 1, 2026
Future Program: Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) | GovScope